References
Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77. https://doi.org/10.1093/neuonc/nox132
Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519–1528. https://doi.org/10.1093/neuonc/noz124
Brand F, Forster A, Christians A, Bucher M, Thome CM, Raab MS et al (2020) FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathol 139:175–192. https://doi.org/10.1007/s00401-019-02067-z
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136:805–810. https://doi.org/10.1007/s00401-018-1913-0
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/NEJMoa1402121
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028
Cimino PJ, Holland EC (2019) Targeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomas. Neuro Oncol. https://doi.org/10.1093/neuonc/noz052
Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B et al (2017) Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol Commun 5:39. https://doi.org/10.1186/s40478-017-0443-7
Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L et al (2015) DNA copy number analysis of grade II–III and grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun 3:34. https://doi.org/10.1186/s40478-015-0213-3
Coons SW, Pearl DK (1998) Mitosis identification in diffuse gliomas: implications for tumor grading. Cancer 82:1550–1555
Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165. https://doi.org/10.1002/1097-0142(19881115)62:10%3c2152:aid-cncr2820621015%3e3.0.co;2-t
Duregon E, Bertero L, Pittaro A, Soffietti R, Ruda R, Trevisan M et al (2016) Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget 7:21190–21198. https://doi.org/10.18632/oncotarget.8498
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279
Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ et al (1999) Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 58:46–53. https://doi.org/10.1097/00005072-199901000-00006
Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ et al (2019) MTAP lsoss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Res 79:3383–3394. https://doi.org/10.1158/0008-5472.CAN-18-1010
Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M et al (2019) Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol Appl Neurobiol 45:108–118. https://doi.org/10.1111/nan.12523
Li KK, Shi ZF, Malta TM, Chan AK, Cheng S, Kwan JSH et al (2019) Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neuro Oncol Adv 1:vdz015. https://doi.org/10.1093/noajnl/vdz015
Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol 133:1–3. https://doi.org/10.1007/s00401-016-1646-x
Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 27:851–852. https://doi.org/10.1111/bpa.12457
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, World Health Organization, International Agency for Research on Cancer (2016) WHO classification of tumours of the central nervous system. International Agency For Research On Cancer, Lyon
Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International society of neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429–435. https://doi.org/10.1111/bpa.12171
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Mirchia K, Snuderl M, Galbraith K, Hatanpaa KJ, Walker JM, Richardson TE (2019) Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Acta Neuropathol Commun 7:121. https://doi.org/10.1186/s40478-019-0778-3
Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol 129:585–596. https://doi.org/10.1007/s00401-015-1398-z
Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ et al (2013) PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol 23:565–573. https://doi.org/10.1111/bpa.12043
Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM et al (2015) CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II–III) astrocytomas. J Neuropathol Exp Neurol 74:442–452. https://doi.org/10.1097/NEN.0000000000000188
Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A et al (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129:867–873. https://doi.org/10.1007/s00401-015-1438-8
Richardson TE, Sathe AA, Kanchwala M, Jia G, Habib AA, Xiao G et al (2018) Genetic and epigenetic features of rapidly progressing IDH-mutant astrocytomas. J Neuropathol Exp Neurol 77:542–548. https://doi.org/10.1093/jnen/nly026
Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J et al (2016) Integrated genomics for pinpointing survival loci within arm-level somatic copy number alterations. Cancer Cell 29:737–750. https://doi.org/10.1016/j.ccell.2016.03.025
Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166. https://doi.org/10.1007/s00401-018-1849-4
Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693. https://doi.org/10.1007/s00401-015-1409-0
Yang RR, Shi ZF, Zhang ZY, Chan AK, Aibaidula A, Wang WW et al (2019) IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol. https://doi.org/10.1111/bpa.12801
Yoda RA, Marxen T, Longo L, Ene C, Wirsching HG, Keene CD et al (2019) Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. J Neuropathol Exp Neurol. https://doi.org/10.1093/jnen/nlz082
Acknowledgements
This paper has been reviewed by the Steering Committee and Clinical Advisory Panel of cIMPACT-NOW [18, 19] and by the International Society of Neuropathology Executive. The authors would like to thank the participants of the cIMPACT-Utrecht meeting, who provided feedback and discussion on the conclusions and recommendations provided in this manuscript: David Capper, Ian Cree, Charles Eberhart, David Ellison, Christine Haberler, Cynthia Hawkins, HK Ng, Brent Orr, Sung-Hye Park, Werner Paulus, Torsten Pietsch, Marc Rosenblum, Brian Rous, Felix Sahm, David Solomon, Uri Tabori, Pieter Wesseling and Valerie White.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Brat, D.J., Aldape, K., Colman, H. et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139, 603–608 (2020). https://doi.org/10.1007/s00401-020-02127-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-020-02127-9